LifeTech Scientific Corporation (HK:1302)
:1302
Want to see HK:1302 full AI Analyst Report?
Top Page
LifeTech Scientific Corporation
(1302)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$2.50
▲(58.23% Upside)
Action:ReiteratedDate:04/28/26
The score is primarily supported by strong recent revenue growth and a very low-leverage balance sheet, alongside bullish technical trend signals. It is held back by meaningful margin/ROE compression and a high P/E valuation with no dividend yield support.
Positive Factors
Revenue Re-acceleration
A durable recovery in top-line (+50.9% YoY in 2025) signals renewed product adoption and market traction for its interventional device portfolio. Sustained revenue growth supports economies of scale, funding for R&D and commercialization, and long-term market share expansion if maintained.
Negative Factors
Material Margin Compression
Steep, persistent margin deterioration erodes the company's ability to convert revenue into profits. If driven by structural cost increases, pricing pressure, or adverse product mix, compressed margins can limit reinvestment, depress sustainable earnings power, and weaken long-term profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Re-acceleration
A durable recovery in top-line (+50.9% YoY in 2025) signals renewed product adoption and market traction for its interventional device portfolio. Sustained revenue growth supports economies of scale, funding for R&D and commercialization, and long-term market share expansion if maintained.
Read all positive factors
LifeTech Scientific Corporation (1302) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$9.16B
Dividend YieldN/A
Average Volume (3M)26.58M
Price to Earnings (P/E)42.5
Beta (1Y)0.92
Revenue Growth5.10%
EPS Growth-32.48%
CountryHK
Employees1,395
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.02
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.74
Price to Sales (P/S)4.59
P/FCF Ratio12.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$1.53B
LifeTech Scientific Corporation Business Overview & Revenue Model
Company Description
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart D...
How the Company Makes Money
The company primarily makes money by selling medical devices used in minimally invasive interventional procedures to hospitals and healthcare providers, generating revenue from the commercialization of its proprietary device portfolio. Revenue is ...
LifeTech Scientific Corporation Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
86
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.33B | 1.30B | 1.27B | 1.10B | 925.33M |
| Gross Profit | 973.70M | 981.43M | 995.64M | 873.93M | 747.53M |
| EBITDA | 255.02M | 271.87M | 253.46M | 445.78M | 397.59M |
| Net Income | 144.00M | 222.39M | 263.24M | 325.34M | 292.47M |
Balance Sheet | |||||
| Total Assets | 5.01B | 4.90B | 4.70B | 3.69B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 1.20B | 1.18B | 1.18B | 833.79M | 1.48B |
| Total Debt | 8.04M | 4.98M | 9.30M | 9.67M | 15.67M |
| Total Liabilities | 1.48B | 1.42B | 1.37B | 769.05M | 653.61M |
| Stockholders Equity | 3.51B | 3.49B | 3.37B | 2.90B | 2.50B |
Cash Flow | |||||
| Free Cash Flow | 501.49M | 38.46M | 125.36M | 52.84M | 145.57M |
| Operating Cash Flow | 555.01M | 321.46M | 418.05M | 388.32M | 488.85M |
| Investing Cash Flow | -73.91M | -517.53M | -453.88M | -458.47M | -86.76M |
| Financing Cash Flow | -383.59M | -116.97M | 182.71M | -215.20M | -256.38M |
LifeTech Scientific Corporation Technical Analysis
Positive
1.58
Price Trends
1.73
Positive
1.72
Positive
1.85
Positive
Market Momentum
0.05
Negative
60.76
Neutral
67.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Positive. The current price of 1.58 is below the 20-day moving average (MA) of 1.78, below the 50-day MA of 1.73, and below the 200-day MA of 1.85, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 60.76 is Neutral, neither overbought nor oversold. The STOCH value of 67.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1302.
LifeTech Scientific Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$7.96B | 27.86 | 4.88% | 0.48% | 35.28% | 146.71% | |
69 Neutral | HK$6.08B | 31.02 | 10.38% | 1.50% | 3.83% | -27.04% | |
68 Neutral | HK$9.16B | 42.52 | 4.02% | ― | 5.10% | -32.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$16.91B | 6.01 | 6.07% | ― | -3.62% | ― | |
43 Neutral | HK$3.29B | -4.06 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:1302
LifeTech Scientific Corporation
2.08
0.66
46.48%
HK:0853
MicroPort Scientific
8.88
2.15
31.95%
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
22.60
4.49
24.76%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.47
-2.03
-45.11%
HK:2172
MicroPort NeuroTech Limited
10.34
0.07
0.68%
LifeTech Scientific Corporation Corporate Events
LifeTech Seeks More Time to Restore Independent Board Compliance
Apr 24, 2026
LifeTech Scientific Corporation, a Cayman Islands-incorporated issuer listed in Hong Kong, is governed by a board that includes executive, non-executive and independent non-executive directors, who also serve on the audit, nomination and remunerat...
LifeTech Scientific Delivers Revenue Growth but Profit Hit by Non-Recurring Charges in 2025
Mar 31, 2026
LifeTech Scientific Corporation, a Hong Kong-listed medical device maker specializing in cardiovascular and endovascular products such as stent grafts, reported modest top-line growth for 2025 driven primarily by higher stent graft sales. The grou...
LifeTech Scientific Sets March Board Meeting to Approve 2025 Results and Discuss Dividend
Mar 12, 2026
LifeTech Scientific Corporation has scheduled a board meeting for 31 March 2026 to review and approve the audited annual results for the year ended 31 December 2025 and to authorize their release on the company’s and the Hong Kong exchange&#...
LifeTech Defends Pricing of Connected Share Purchases Amid Sector Volatility
Feb 27, 2026
LifeTech Scientific Corporation has issued a supplemental announcement detailing pricing considerations for a connected share purchase under its share award scheme, following earlier transactions in June 2024 and December 2025. The company explain...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.